GlassScriptPhysician profile
Andrew J Moore
NPI 1881813202
$8,956.33
in general payments reported to CMS, 2019-2025
43 companies · $1,289 in 2025
The $1,289 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $802 · 2020: $425 · 2021: $322 · 2022: $1,211 · 2023: $4,056 · 2024: $851 · 2025: $1,289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,237 · Consulting Fee: $2,498 · Education: $251 · Travel and Lodging: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,237.43 |
| Consulting Fee | $2,497.50 |
| Education | $251.34 |
| Travel and Lodging | $210.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,089.99 | 2019-2025 | Calquence, Enhertu, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $942.87 | 2019-2025 | Opdivo, Opdualag |
| Novartis Pharmaceuticals Corporation | $684.85 | 2019-2025 | |
| Incyte Corporation | $486.35 | 2019-2025 | Monjuvi, Jakafi, Monjuvi |
| Reflexion Medical, INC. | $444.00 | 2022 | |
| Abbvie INC. | $422.78 | 2019-2025 | |
| Janssen Biotech, INC. | $422.58 | 2019-2025 | Rybrevant, Carvykti, Darzalex |
| Merck Sharp & Dohme LLC | $302.26 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Genzyme Corporation | $201.20 | 2019-2023 | |
| Amgen INC. | $185.52 | 2019-2024 | Prolia, Evenity, Nplate |
| Eisai INC. | $174.70 | 2020-2025 | |
| Seagen INC. | $171.82 | 2020-2023 | |
| Celgene Corporation | $152.93 | 2022-2025 | Reblozyl |
| Tempus Ai, INC | $137.01 | 2025 | Xt Cdx |
| Adc Therapeutics America, INC. | $116.70 | 2022 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $103.14 | 2021-2023 | Libtayo |
| Genentech USA, INC. | $102.30 | 2023-2025 | Polivy, Lunsumio, Venclexta |
| Stemline Therapeutics INC. | $94.10 | 2023-2024 | Orserdu |
| Jazz Pharmaceuticals INC. | $69.31 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $66.87 | 2022-2023 | Fotivda |
| Dendreon Pharmaceuticals LLC | $65.16 | 2023 | Provenge |
| Gilead Sciences, INC. | $59.20 | 2021-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $40.86 | 2023 | Ojjaara, Shingrix |
| Rigel Pharmaceuticals, INC. | $39.71 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Beigene USA, INC. | $36.46 | 2023-2025 | Brukinsa |
| Array Biopharma INC | $32.54 | 2024-2025 | Mektovi, Braftovi, Xalkori |
| Emd Serono, INC. | $31.85 | 2020 | |
| Pfizer INC. | $27.76 | 2025 | |
| Puma Biotechnology, INC. | $23.77 | 2020 | |
| Daiichi Sankyo INC. | $18.81 | 2025 | Datroway |
| Takeda Pharmaceuticals U.S.A., INC. | $18.45 | 2025 | Fruzaqla |
| Immunomedics, INC. | $18.43 | 2020 | |
| Mirati Therapeutics, INC. | $18.43 | 2023 | Krazati |
| Kyowa Kirin, INC. | $17.81 | 2023 | Poteligeo |
| Exelixis INC. | $17.52 | 2019 | |
| Kite Pharma, INC. | $17.51 | 2022 | |
| Servier Pharmaceuticals LLC | $16.54 | 2024 | |
| Aadi Bioscience, INC. | $15.52 | 2022 | |
| Progenics Pharmaceuticals, INC. | $15.01 | 2022 | |
| Astellas Pharma US INC | $14.69 | 2025 | Xtandi |
| Alexion Pharmaceuticals, INC. | $13.76 | 2019 | |
| Karyopharm Therapeutics INC. | $13.16 | 2020 | |
| Agios Pharmaceuticals, INC. | $12.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.